Do you want to read an article? Please log in or register.
Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes
Macular Diseases
Related content
Macular DiseasesRetinal Diseases
Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes
Sci Rep
Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST
doi: 10.1038/s41598-025-20300-6
Macular Diseases
Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema
Br J Ophthalmol
Chalkiadaki E, Sim YS, Williams O, Elder L, Addison PK, Hamilton RD, Nicholson L, Sivaprasad S, Heng LZ
doi: 10.1136/bjo-2025-328893
Macular Diseases
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report
Ophthalmol Sci
Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG
doi: 10.1016/j.xops.2026.101087
Glaucoma and Ocular Pressure
Risk of Dementia in Type 2 Diabetes Patients with Open-Angle Glaucoma: Insights from a Nationwide Real-World Cohort Study
Am J Ophthalmol
Zhou J, Lee DA, Talebi Y, Wu G, Wu H
doi: 10.1016/j.ajo.2026.02.003
Macular DiseasesRetinal Diseases
Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review
Surv Ophthalmol
Nanji K, Hatamnejad A, Grad J, El-Sayes A, Mihalache A, Gemae M, Huang R, Phillips M, Zeraatkar D, Singh R, Munk MR, Sadda SR, Sarraf D, Kaiser P, Guymer R, Sivaprasad S, Fraser-Bell S, Tham YC, Garg SJ, Wong TY, Wykoff CC, Chaudhary V
doi: 10.1016/j.survophthal.2025.09.009
Macular Diseases
Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry
Ophthalmol Ther
Timoceanu L, Steinmann S, Gillies MC, Barthelmes D
doi: 10.1007/s40123-026-01449-3
RECOMMENDED
Retinal Diseases
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy
★ 3
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
Am J Ophthalmol
Shah J, Makwana B, Panchal K, Patel V, Patel T, Khadke S, Verma A, Vivekanandan S, Kong Y, Upadhyay J, Dani SS, Ramsey KM, Ganatra S, Ramsey DJ
doi: 10.1016/j.ajo.2026.04.021
Macular DiseasesFurther Publications
Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence
BMC Ophthalmol
Owlya N, Barbosa M, Bartolomeo N, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Barry MP, Ambresin A
doi: 10.1186/s12886-026-04651-w
Retinal Diseases
Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence
J Clin Endocrinol Metab
Tan L, Cooper JM, Gokhale K, Sainsbury C, Denniston AK, Toulis KA, Crowe FL, Nirantharakumar K, Wang J
doi: 10.1210/clinem/dgag367